VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

Researchers use hydrogels to induce significant vasculature growth in areas of damaged tissue

Regenerative medicine therapies often require the growth of functional, stable blood vessels at the site of an injury. Using synthetic polymers called hydrogels, researchers at the Georgia Institute of Technology have been able to induce significant vasculature growth in areas of damaged tissue.

22 Dec 2009

Reference platform for diabetic retinopathy and other vascular complications

The volume addresses a variety of current scientific discussions about mechanisms of damage such as growth factors and the VEGF/PEDF balance in the diabetic eye, the ocular renin-angiotensin system, and leukocyte interactions with the microvasculature among others.

22 Dec 2009

Cellular and subcellular effects of PACE technology presented

SANUWAVE Health, Inc., (www.sanuwave.com), an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, announced that the cellular and subcellular effects of PACE™ technology were described during a lecture presented this past weekend.

15 Dec 2009

Molecular Partners closes its CHF 46 million Series B equity investment round

Molecular Partners AG, a pioneer in the development of DARPins as next generation protein therapeutics, has announced the closing of its Series B equity investment round securing CHF 46 million (€ 30 million, $ 45 million).

15 Dec 2009

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study (RIBBON 2) of Avastin® (bevacizumab) in women who had previously been treated with initial (first-line) chemotherapy for advanced HER2-negative breast cancer and needed additional (second-line) treatment.

14 Dec 2009

Preclinical graft study supports Cytori’s proposed mechanism of action

Cytori Therapeutics reported results from a preclinical cell-enriched fat grafting study supporting the safety and efficacy of Cytori’s method for enriching fat grafts with adipose-derived regenerative cells (ADRCs).

14 Dec 2009

Preliminary data from Phase 2 clinical trial of ZFP Therapeutic program presented

Sangamo BioSciences, Inc. announced today the presentation of preliminary data from the Phase 2 clinical trial of its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for amyotrophic lateral sclerosis (ALS) at a Work in Progress session at the 20th International Symposium on ALS/MND held in Berlin, Germany.

9 Dec 2009

iCo Therapeutics to present an overview of its iCo-007 VEGF "+" agent at the ISOPT conference

iCo Therapeutics Inc. is pleased to announce that an overview of iCo-007, entitled "iCo-007 a VEGF "+" Agent for the Potential Treatment of Diabetic Macular Edema and Diabetic Retinopathy" will be presented at the 8th International Symposium on Ocular Pharmacology and Therapeutics ("ISOPT"), a major international ocular conference.

3 Dec 2009

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Novartis announced today that new data, including a late-breaking presentation on Tasigna® (nilotinib) 200 mg capsules in a form of chronic myeloid leukemia, demonstrate the strength of the company's hematology portfolio in advancing the care of patients.

2 Dec 2009

Neurotoxic heavy metal can slow the progression of Lou Gehrig's disease

New discoveries have been made about how an elevated level of lead, which is a neurotoxic heavy metal, can slow the progression of amyotrophic lateral sclerosis, or Lou Gehrig's disease - findings that could point the way to a new type of therapy.

1 Dec 2009

New target may promote development of novel therapies for chronic sinusitis

A protein known to stimulate blood vessel growth has now been found to be responsible for the cell overgrowth in the development of polyps that characterize one of the most severe forms of sinusitis, a study by Johns Hopkins researchers suggests. The finding gives scientists a new target for developing novel therapies to treat this form of the disease, which typically resists all current treatments.

23 Nov 2009

New biomarkers can predict patients' response to certain drugs

Recent advances in cancer therapeutics have led to the discovery of biomarkers that can predict patient response to certain drugs. Screening for mutations in the epidermal growth factor receptor (EGRF) prior to non-small cell lung cancer treatment, for example, has been shown to indentify patients who are likely to respond to treatment with erlontinib. This maximizes the drug's impact, and spares patients who are not likely to benefit from being subjected to potentially debilitating side effects.

19 Nov 2009

New pre-clinical data from Alnylam Pharmaceuticals' ALN-VSP program presented

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced new pre-clinical data from its ALN-VSP program presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International conference being held November 15 - 19, 2009 in Boston, Mass.

18 Nov 2009

Press conference highlights emerging treatments in pancreatic cancer

As part of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Thompson will moderate a press conference on emerging treatments in pancreatic cancer on Tuesday, Nov. 17, 2009, in Room 202 of the Hynes Convention Center in Boston, Mass., from 1:00 p.m. to 2:00 p.m. ET.

18 Nov 2009

Study to test anti-tumor effects of AEOL 10150 initiated

Aeolus Pharmaceuticals, Inc. announced today the initiation of a study to test the anti-tumor effects of AEOL 10150 when combined with radiation and chemotherapy in nude mice bearing human non-small cell lung cancer (NSCLC) xenografts.

18 Nov 2009

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

To highlight results of more recent research, the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference will host a press briefing on "Drugs in the Pipeline." Sara A. Courtneidge, Ph.D., D.Sc., professor and director of the Tumor Microenvironment Program, and director of academic affairs at the Burnham Institute for Medical Research, will moderate this press briefing.

17 Nov 2009

Genentech submits sBLAs to the FDA for Avastin

Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the Phase III study AVADO that investigated Avastin in combination with docetaxel chemotherapy.

17 Nov 2009

Compugen signs research and license agreement with a leading diagnostic company

Compugen Ltd. announced today that it has signed a research and license agreement with a leading diagnostic company covering CGEN-226, a novel biomarker candidate for early detection of preeclampsia.

5 Nov 2009

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi.

5 Nov 2009

Acceleron Pharma commences Phase 1 clinical study of its novel angiogenesis inhibitor

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced the initiation of a Phase 1 clinical study of ACE-041, a novel angiogenesis inhibitor that binds to and prevents members of the TGF-β superfamily from signaling through the activin receptor-like kinase 1 (ALK1) receptor.

4 Nov 2009